Amarin has chosen top notch Cardiologists to conduct studies.
1) Dr.Ballantyne conducted Anchor 3 trials.His comments in media/professional circles carry a lot of weight.
2) Dr.Bhatt is conducting Reduce-It study.He is trained at Cleveland Clinic(#1 in USA) and currently at Harvard. burst.to/eB explains why past studies with Fish oil have done poorly.
He is making sure that Reduce-It study is done correctly.
I think--Early results in 2014 will be similar to Crestor-Jupiter study.Reduce-It study could raise the Sales potential by 2 billion$ as soon as FDA approves in 2015.
If you look at the criteria for enrolling a patient--you will realize it is limited to certain subgroup of patients(who have suffered an attack before).
So watch Reduce-It study enrollment. Doing it in Europe/Asia etc.raises extra effort-so Amarin hired a person recently--to communicate with them. Enrollment announcement should help the share price.